339 related articles for article (PubMed ID: 29477393)
1. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
[TBL] [Abstract][Full Text] [Related]
2. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
3. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
Neumann PJ; Willke RJ; Garrison LP
Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
Garrison LP; Pauly MV; Willke RJ; Neumann PJ
Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
[TBL] [Abstract][Full Text] [Related]
5. ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.
Solow B; Pezalla EJ
Value Health; 2018 Feb; 21(2):166-168. PubMed ID: 29477395
[No Abstract] [Full Text] [Related]
6. ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.
Perfetto EM
Value Health; 2018 Feb; 21(2):169-170. PubMed ID: 29477396
[No Abstract] [Full Text] [Related]
7. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.
Burkholder R; Dougherty JS; Neves LA
Value Health; 2018 Feb; 21(2):173-175. PubMed ID: 29477398
[No Abstract] [Full Text] [Related]
8. Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
Phelps CE; Lakdawalla DN; Basu A; Drummond MF; Towse A; Danzon PM
Value Health; 2018 Feb; 21(2):146-154. PubMed ID: 29477392
[TBL] [Abstract][Full Text] [Related]
9. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
Sculpher M
Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
[No Abstract] [Full Text] [Related]
10. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
Danzon PM; Drummond MF; Towse A; Pauly MV
Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
[TBL] [Abstract][Full Text] [Related]
11. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
[TBL] [Abstract][Full Text] [Related]
12. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
Garrison LP; Neumann PJ; Willke RJ
J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
[TBL] [Abstract][Full Text] [Related]
13. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
14. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
16. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
17. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
18. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
19. The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis.
Neumann PJ; Garrison LP; Willke RJ
Value Health; 2022 Apr; 25(4):558-565. PubMed ID: 35279370
[TBL] [Abstract][Full Text] [Related]
20. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
